The main markers of treatment response that have been investigated in ACC are expression of like programmed death-1 (PD-1) and its ligand PD-L1, microsatellite instability (MSI) and tumor mutational burden (TMB) [67] (Table 1). This evidence concerns the gene PDCD1 and adrenal cortex carcinoma.